Cargando…
Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial
OBJECTIVE: To compare the efficacy of Food and Drug Administration recommended dosing of nicardipine versus labetalol for the management of hypertensive patients with signs and/or symptoms (S/S) suggestive of end-organ damage (EOD). DESIGN: Secondary analysis of the multicentre prospective, randomis...
Autores principales: | Cannon, Chad M, Levy, Phillip, Baumann, Brigitte M, Borczuk, Pierre, Chandra, Abhinav, Cline, David M, Diercks, Deborah B, Hiestand, Brian, Hsu, Amy, Jois, Preeti, Kaminski, Brian, Nowak, Richard M, Schrock, Jon W, Varon, Joseph, Peacock, W Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612758/ https://www.ncbi.nlm.nih.gov/pubmed/23535700 http://dx.doi.org/10.1136/bmjopen-2012-002338 |
Ejemplares similares
-
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department
por: Peacock, W Frank, et al.
Publicado: (2011) -
Inadvertent intrathecal injection of labetalol
por: Verma, S, et al.
Publicado: (2016) -
Considerations for initial therapy in the treatment of acute heart failure
por: Peacock, William F., et al.
Publicado: (2015) -
Retrospective evaluation of labetalol as antihypertensive agent in dogs
por: Zublena, Francesco, et al.
Publicado: (2020) -
Safety and Tolerability of Concentrated Intraventricular Nicardipine for Poor-Grade Aneurysmal Subarachnoid Hemorrhage–Related Vasospasm
por: Zahra, Kaneez, et al.
Publicado: (2023)